Andrew A. Davis, MD, Washington University School of Medicine, St. Louis, MOm discusses future approaches in the use of next-generation sequencing and circulating tumor DNA (ctDNA) in the treatment and management of breast cancer, such as disease monitoring and minimal residual disease (MRD). This interview took place at the San Antonio Breast Cancer Symposium 2021 in San Antonio.
